Bio­Marin lays off 120 staffers to 'sim­pli­fy' the com­pa­ny while FDA re­views its big gene ther­a­py

By the time the FDA hands down its de­ci­sion on val­rox, Bio­Marin will be a dif­fer­ent com­pa­ny — lit­er­al­ly.

The biotech is lay­ing off about 120 em­ploy­ees — 4% of its glob­al work­force — in a slim down that will save about $50 mil­lion an­nu­al­ly. A “sig­nif­i­cant por­tion” of the sav­ings, it adds, will go to­ward its clin­i­cal de­vel­op­ment port­fo­lio, ear­ly-stage pipeline, as well as the com­mer­cial launch­es and val­rox, the he­mo­phil­ia A gene ther­a­py that al­ready has the brand name Roc­ta­vian.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER